Boom or Bust: Canada’s Hottest Stocks Today – and the Biotech Name Quietly Climbing 🍁

Toronto – Canadian markets are roaring into the end of Q3 with high momentum. The S&P/TSX Composite Index flirted with the 30,000 mark after yet another record close, buoyed by strong gains in technology, mining, and an eye-popping rally in cannabis stocks. Investor sentiment is risk-on as upbeat economic signals and sector-specific catalysts drive sharp moves in individual names. Below we highlight the top five boom-or-bust stocks trending on Bay Street today – plus one under-the-radar biotech that’s steadily gaining notice.

To set the scene, here’s a quick snapshot of today’s standout movers on the TSX and TSX Venture:

Tilray Brands (TSX: TLRY) – Cannabis Soars on U.S. Policy Buzz

It was boom time for cannabis stocks, and Tilray led the charge. Shares of this Canadian pot producer skyrocketed – up over 40% intraday and nearly 60% by closing – as U.S. President Donald Trump gave the sector an unlikely jolt. In a surprise social media post, Trump hailed cannabidiol (CBD) as a “gamechanger” for senior healthcare, even floating Medicare coverage for CBD products. That political green light ignited a speculative frenzy across pot stocks. Tilray’s double-digit surge reflects renewed optimism that U.S. cannabis reforms (like reclassifying marijuana as a lower-risk drug) could finally be on the horizon, unlocking growth in the massive American market. For investors, Tilray’s explosive move shows how quickly policy news can light a fire under beaten-down sectors – a classic high-risk, high-reward boom.

Curaleaf Holdings (TSX: CURA) – Index Debut and Policy Spark

Curaleaf – one of the world’s largest cannabis companies – also enjoyed a breakout rally, riding the same CBD news to a 34% jump in Toronto trading. As a U.S.-based operator newly listed on the TSX, Curaleaf is making history as the first American cannabis firm added to the TSX Composite Index (a milestone it hit last week). That index inclusion is boosting Curaleaf’s visibility among institutional investors, increasing trading volumes and liquidity. Then came Trump’s CBD endorsement, sparking a broad “risk-on” re-rating for cannabis. Curaleaf’s big pop underscores how multiple catalysts converged – an expanding investor base plus a jolt of regulatory optimism. While still unprofitable, the company’s international footprint and pending U.S. reforms have traders speculating this could be a long-term winner. Curaleaf’s volatile ascent epitomizes the boom side of today’s market – huge upside on a headline, tempered by equally high uncertainty.

First Quantum Minerals (TSX: FM) – Copper Giant Breaks Out

First Quantum put some shine on the materials sector, with its stock hitting a fresh 52-week high after rallying about 7%. The catalyst? A bullish analyst upgrade – Jefferies hiked its price target on the copper miner to C$33 and reiterated a Buy, citing stronger outlook for First Quantum’s massive projects. Investors piled in, anticipating that improving commodity prices and production milestones (like progress at its Cobre Panama mine) will boost earnings. The TSX’s heavy weighting in resources means moves in names like First Quantum also reflect macro optimism. Copper prices have been firm, thanks to global growth hopes and electrification trends, adding tailwinds. First Quantum’s surge to C$31+ signals a technical breakout, clearing previous highs on strong volume. With multiple brokerages raising targets and the stock up ~30% year-to-date, this base-metals bellwether is a momentum play to watch.

Hudbay Minerals (TSX: HBM) – Metals Rally Lifts All Boats

Another mining winner today was Hudbay Minerals, which climbed to a new 2025 peak at C$21.20 (about a 7.4% gain on the day). The base metals miner – with operations from copper in Peru to zinc in Manitoba – has quietly been on a tear. Hudbay’s stock has now more than doubled from its 52-week low of C$0.06 (after a reverse split), reflecting a dramatic turnaround in sentiment. What’s driving it? A mix of firm commodity prices and growing confidence in management’s strategy. Analysts have been upgrading Hudbay’s outlook and hiking price targets (the consensus target was recently raised to ~C$17.25), highlighting improved production and cash flow. The company even initiated a modest dividend, underscoring financial strength. Today’s pop likely also reflects a sector-wide rotation into cyclical stocks – investors betting that demand for industrial metals will stay strong into 2026. For a traditionally volatile mid-cap miner, Hudbay’s steady climb is a positive sign – but with a beta over 2.0, it can still swing with commodity prices. In short, it’s a boom story built on real fundamentals this time around.

Barrick Gold (TSX: ABX) – Leadership Shock Amid Gold Rush

Not every top mover was to the upside. Barrick Gold, one of Canada’s largest miners, saw its stock slide about 4% – making it a notable bust on an otherwise bullish day. Ironically, this drop came even as gold prices hit record highs. The culprit was company-specific: Barrick’s legendary CEO Mark Bristow abruptly resigned, with the board installing a veteran executive as interim chief. The surprise leadership shake-up injected uncertainty, prompting some investors to take profits despite the favorable gold price environment. Barrick had been outperforming earlier in the year (thanks to surging bullion prices and solid production), so the sudden C-suite change caught the market off guard. Still, many analysts see the dip as temporary given Barrick’s world-class asset base. In the boom-or-bust narrative, Barrick’s news shows that even a gold miner isn’t immune to corporate drama. The stock’s pullback is a reminder that leadership and execution matter – and that today’s market will punish negative surprises swiftly, even for blue-chip names.

Hemostemix (TSXV: HEM) – A Quiet Climber in Biotech

Not among today’s high flyers, Hemostemix is nevertheless a biotech penny stock earning a spot on savvy investors’ watchlists. Trading around C$0.10 per share, this TSX Venture-listed company is developing an autologous stem-cell therapy (ACP-01) to treat severe vascular diseases like critical limb ischemia and angina. Why watch Hemostemix now? For one, insiders are showing confidence – just weeks ago a company director scooped up 260,000 shares at $0.08, bringing his stake to nearly 22 million shares. The firm also struck a deal to settle debt by issuing shares at C$0.20 – double the current market price – signaling that creditors (and management) see upside potential. Meanwhile, Hemostemix has been hitting milestones: it’s in Phase II trials for ACP-01 and recently presented promising clinical data on treating angina. The company is expanding its reach too, launching a U.S. patient treatment initiative in Florida and applying to up-list to the OTCQB market for greater liquidity. All this activity has the stock quietly climbing off its summer lows. As a micro-cap biotech, Hemostemix carries high risk, but these developments position it as an intriguing speculative play. In a market obsessed with big daily movers, HEM is a reminder that some winners build over time, not overnight.

Key Takeaway: Monitor This Watchlist

Today’s market action in Canada showcased both sizzle and substance. Explosive moves in cannabis and mining stocks prove that catalysts – from policy bombshells to analyst upgrades – can ignite rapid gains. At the same time, corporate shake-ups (Barrick) and small-cap breakthroughs (Hemostemix) highlight the importance of stock-picking beyond the headlines. Investors would be wise to monitor these names in the coming weeks. Will the cannabis rally fizzle or find new fuel? Can mining stocks sustain momentum if commodity prices waver? And will Hemostemix’s steady progress translate into outsized returns? Stay tuned – this watchlist is a microcosm of the opportunities and risks dotting the Canadian market landscape. As we head into the final quarter, keep an eye on the boom, beware the bust, and don’t overlook the quiet climbers poised to surprise.

HEMOSTEMIX DISCLAIMER: Disclosure: Lusso’s News, LLC(“EMV”) has been compensated by Hemostemix Inc. (“Hemostemix”) in the amount of $5,000 USD per month, commencing August 13, 2025, and continuing through September 31, 2025, with the possibility of extension until further notice. This compensation is for the creation and dissemination of content about Hemostemix, including but not limited to articles, website postings, social media updates, and other promotional materials.
The content produced by EMV is intended solely for informational purposes. It does not constitute an offer to sell, a solicitation to buy, or a recommendation regarding any security, investment product, or trading strategy. EMV is not a registered investment adviser or broker-dealer, and nothing in this content should be construed as personalized investment advice.
Investing in securities involves risks, including the potential loss of principal. Readers should conduct their own independent research, perform due diligence, and consult with a licensed financial adviser, attorney, or tax professional before making any investment decisions.
EMV’s compensation from Hemostemix presents a conflict of interest as EMV has a financial incentive to promote Hemostemix. As a result, the content may be biased and should not be relied upon as independent or impartial.
By accessing this content or the associated website, you acknowledge and agree to the terms of this disclaimer.